Sezary Syndrome - 12 Studies Found

Terminated : Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
:
  • Sezary Syndrome
  • Pruritus

: 2012-06-19
:
  • Drug: Aprepitant Aprepitant wi
Completed : Immunization Against Tumor Cells in Sezary Syndrome
:
  • Cutaneous T-cell Lymphoma
  • Sezary Syndrome

: 2004-12-17
: Biological: Autologous Dendritic Cell Vaccine
Completed : VircapSeq Virus Detection in Sézary Syndrome
:
  • Lymphoma, T-Cell, Cutaneous
  • Sézary Syndrome

: 2016-07-15
Terminated : Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome
: Lymphoma
: 1999-12-10
: Drug: temozolomide Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a to
Completed : Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome
: Lymphoma
: 1999-11-01
: Drug: tretinoin
Terminated : Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
: Lymphoma
: 2000-06-02
: Biological: aldesleukin
Active, not recruiting : Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
: Lymphoma
: 2003-04-07
: Biological: alemtuzumab Will be administered as a two-hour IV infusion with a target dose of 30 milligra
Not yet recruiting : Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
:
  • Recurrent Mycosis Fungoides and Sezary Syndrome
  • Refractory Myco
    : 2017-02-22
    :
    • Biological: Interferon Gamma-1b

Active, not recruiting : Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
: Lymphoma
: 2007-04-25
: Drug: lenalidomide 10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cy
Completed : Effect of Denileukin Diftitox on Immune System in CTCL Patients
:
  • Cutaneous T-cell Lymphoma
  • Sezary Syndrome